Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study

Category Primary study
JournalJournal of Clinical Oncology
Year 2020
This article has no abstract
Epistemonikos ID: ddbf7c30b5a4db410dbe3dc474486c43c5b0e0cf
First added on: Feb 12, 2025